Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
SFZN Stock Overview
Siegfried Holding AG engages in the life sciences business worldwide.
Siegfried Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF707.00 |
52 Week High | CHF923.00 |
52 Week Low | CHF566.00 |
Beta | 0.80 |
1 Month Change | 7.61% |
3 Month Change | 14.31% |
1 Year Change | -23.19% |
3 Year Change | 84.60% |
5 Year Change | 150.49% |
Change since IPO | 830.26% |
Recent News & Updates
Should You Be Adding Siegfried Holding (VTX:SFZN) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Shareholder Returns
SFZN | CH Life Sciences | CH Market | |
---|---|---|---|
7D | 1.4% | -0.6% | -0.6% |
1Y | -23.2% | -29.5% | -13.6% |
Return vs Industry: SFZN exceeded the Swiss Life Sciences industry which returned -28.7% over the past year.
Return vs Market: SFZN underperformed the Swiss Market which returned -12.9% over the past year.
Price Volatility
SFZN volatility | |
---|---|
SFZN Average Weekly Movement | 5.2% |
Life Sciences Industry Average Movement | 6.5% |
Market Average Movement | 4.5% |
10% most volatile stocks in CH Market | 7.8% |
10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: SFZN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: SFZN's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1873 | 3,488 | Wolfgang Wienand | https://www.siegfried.ch |
Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production.
Siegfried Holding AG Fundamentals Summary
SFZN fundamental statistics | |
---|---|
Market Cap | CHF3.00b |
Earnings (TTM) | CHF95.60m |
Revenue (TTM) | CHF1.10b |
31.4x
P/E Ratio2.7x
P/S RatioIs SFZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SFZN income statement (TTM) | |
---|---|
Revenue | CHF1.10b |
Cost of Revenue | CHF862.85m |
Gross Profit | CHF239.57m |
Other Expenses | CHF143.97m |
Earnings | CHF95.60m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 18, 2022
Earnings per share (EPS) | 22.51 |
Gross Margin | 21.73% |
Net Profit Margin | 8.67% |
Debt/Equity Ratio | 69.7% |
How did SFZN perform over the long term?
See historical performance and comparison